TED-A9 is an investigational therapy consisting of dopaminergic neuron precursors derived from human embryonic stem cells. These precursors are generated in a laboratory and have the potential to differentiate into various cell types under appropriate conditions.
The therapy is surgically implanted into the brain’s putamen region, where the precursors should mature into functional dopaminergic neurons. The approach is intended to alleviate the motor symptoms associated with Parkinson’s disease by replacing lost neurons.